RxDoctor Payments Data

Natalia Pasumansky

Family · Redmond, WANPI 1366417909

Payments from drug & device makers

$318in general payments, 2019–2025

Across 15 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$63
  • Novo Nordisk$47
  • Kowa Pharmaceuticals America, Inc.$45
  • Organogenesis Inc.$44
  • Bayer$30
  • Hologic Sales And Service, LLC$23
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$318 in reported general payments places this provider in the 60th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$11,803
Medicare patients
44
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$88,643
TrulicityDulaglutide63$67,199
CreonLipase/Protease/Amylase24$67,104
FarxigaDapagliflozin Propanediol93$64,193
JardianceEmpagliflozin60$51,509
LinzessLinaclotide44$40,435
ProliaDenosumab18$31,926
MyrbetriqMirabegron28$19,639
JanuviaSitagliptin Phosphate25$17,766
EliquisApixaban12$14,084
Breo ElliptaFluticasone/Vilanterol32$13,129
SymbicortBudesonide/Formoterol Fumarate46$10,867
Tresiba Flextouch U-200Insulin Degludec15$9,209
VascepaIcosapent Ethyl25$8,927
Advair HfaFluticasone Propion/Salmeterol23$7,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$63$107,53968 claims
Novo NordiskOzempic$47$88,64389 claims
Boehringer IngelheimJardiance$20$51,50960 claims
GSKBreo Ellipta$19$13,12932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,706 family providers in Washington.

Other family in Redmond

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →